Vice President, Epidemiology in Worldwide Safety and Regulatory, Pfizer R&D
Dr. Reynolds is Vice President, Epidemiology in Worldwide Safety and Regulatory, part of Research and Development at Pfizer. He heads a group of epidemiologists and statistical analysts responsible for developing epidemiologic programs to support drug development and safety assessment. He is also an Adjunct Associate Professor of Epidemiology at Tulane School of Public Health and Tropical Medicine where he teaches pharmacoepidemiology. He is a Fellow and former Board member of the International Society for Pharmacoepidemiology. Prior to joining the pharmaceutical industry, he was a Saltonstall Fellow at the Harvard Center for Population and Development Studies. He holds a BA in Biology from Bard College and a MSc in Epidemiology and ScD in Population and International Health from the Harvard School of Public Health.
Pharmaceutical industry and regulators use decision analysis within their organizations to support complex benefit risk decision-making. Systematic use of quantitative benefit risk assessment is possible in future interactions between these stakeholders. Regulators are exploring ways in which quantitative decision analysis approaches, methods and tools can be used to inform benefit risk assessment and decision making […]